FOLFIRINOX as a first line therapy in locally advanced pancreatic cancer and borderline resectable pancreatic cancer: a Meta-analysis

Abstract

Objective To evaluate the efficacyof the first line chemotherapy FOLFIRINOX (5-Fu, Leucovorin calcium, Irinotecan, Oxaliplatin) as the treatment of pancreatic cancer. Methods Pertinent studies were identified from the PubMed, Cochrane Library and EMBASE. The outcomes were resection rate and radical (R0) resection rate were analyzed. Data were expressed as weighted pooled proportions with 95% confidence intervals (95%CI). Results There were thirteen studies with 408 patients with LAPC and BRPC included. After the treatment, 42.0% (95% CI: 28.0%~56.0%) tumorswere resected and 41.0% (95% CI: 37.0%~45.0%) were underwentR0 resection, and median overall survival ranged from 15.5 to 34.5 months, median progression-free survival ranged from 10.0 to 17.8 months. Conclusion The meta-analysis shows that down-staging after first line FOLFIRINOX-based therapy is noticeable in patients with borderline resectable/unresectable PC, and the adverse events were in control. Key words: Pancreatic cancer; FOLFIRINOX; Resection; Chemotherapy